Hepatic Encephalopathy clinical trials at UCSD

1 research study open to eligible people

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
open to eligible people ages 18 years and up
The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.
La Jolla, California and other locations

Our lead scientists for Hepatic Encephalopathy research studies include Michael Mendler, MD.

Last updated: September 2022

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy